{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T07:25:39Z","timestamp":1794036339229,"version":"4.8.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100014383","name":"Italfarmaco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014383","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40273-026-01610-7","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T17:51:32Z","timestamp":1774720292000},"page":"817-837","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Economic Burden of Duchenne Muscular Dystrophy: A Systematic Review"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5758-7151","authenticated-orcid":false,"given":"Erik","family":"Landfeldt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"\u00c5berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Deroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred Peter","family":"Born","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silene","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Berit","family":"Ekstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"key":"1610_CR1","doi-asserted-by":"crossref","unstructured":"Okubo M. Molecular genetics of dystrophinopathy. J Hum Genet. 2025.","DOI":"10.1038\/s10038-025-01357-7"},{"issue":"10119","key":"1610_CR2","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(17)32160-8","volume":"391","author":"CM McDonald","year":"2018","unstructured":"McDonald CM, Henricson EK, Abresch RT, Duong T, Joyce NC, Hu F, et al. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study. Lancet. 2018;391(10119):451\u201361.","journal-title":"Lancet"},{"issue":"1","key":"1610_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3233\/JND-230094","volume":"11","author":"E Landfeldt","year":"2024","unstructured":"Landfeldt E, Aleman A, Abner S, Zhang R, Werner C, Tomazos I, et al. Factors associated with respiratory health and function in Duchenne muscular dystrophy: a systematic review and evidence grading. J Neuromuscul Dis. 2024;11(1):25\u201357.","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"1610_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s13023-024-03372-x","volume":"19","author":"E Landfeldt","year":"2024","unstructured":"Landfeldt E, Alem\u00e1n A, Abner S, Zhang R, Werner C, Tomazos I, et al. Predictors of cardiac disease in Duchenne muscular dystrophy: a systematic review and evidence grading. Orphanet J Rare Dis. 2024;19(1):359.","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"1610_CR5","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10654-020-00613-8","volume":"35","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Thompson R, Sejersen T, McMillan HJ, Kirschner J, Lochm\u00fcller H. Life expectancy at birth in Duchenne muscular dystrophy: a systematic review and meta-analysis. Eur J Epidemiol. 2020;35(7):643\u201353.","journal-title":"Eur J Epidemiol"},{"issue":"7","key":"1610_CR6","doi-asserted-by":"publisher","first-page":"4300","DOI":"10.1007\/s00415-024-12372-7","volume":"271","author":"L Wahlgren","year":"2024","unstructured":"Wahlgren L, Kroksmark AK, Lindblad A, Tulinius M, Sofou K. Respiratory comorbidities and treatments in Duchenne muscular dystrophy: impact on life expectancy and causes of death. J Neurol. 2024;271(7):4300\u20139.","journal-title":"J Neurol"},{"key":"1610_CR7","doi-asserted-by":"crossref","unstructured":"Montagna C, Maiani E, Pieroni L, Consalvi S. Duchenne muscular dystrophy: integrating current clinical practice with future therapeutic and diagnostic horizons. Int J Mol Sci. 2025;26(14).","DOI":"10.3390\/ijms26146742"},{"issue":"3","key":"1610_CR8","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","volume":"17","author":"DJ Birnkrant","year":"2018","unstructured":"Birnkrant DJ, Bushby K, Bann CM, Apkon SD, Blackwell A, Brumbaugh D, et al. Diagnosis and management of Duchenne muscular dystrophy, Part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251\u201367.","journal-title":"Lancet Neurol"},{"issue":"10","key":"1610_CR9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1111\/dmcn.13934","volume":"60","author":"E Landfeldt","year":"2018","unstructured":"Landfeldt E, Edstr\u00f6m J, Buccella F, Kirschner J, Lochm\u00fcller H. Duchenne muscular dystrophy and caregiver burden: a systematic review. Dev Med Child Neurol. 2018;60(10):987\u201396.","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"1610_CR10","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","volume":"12","author":"S Ryder","year":"2017","unstructured":"Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1):79.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1610_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13023-018-0975-3","volume":"14","author":"E Landfeldt","year":"2019","unstructured":"Landfeldt E, Lochm\u00fcller H, Lindgren P. Incomplete description of the current body of evidence of the health economics of Duchenne muscular dystrophy. Orphanet J Rare Dis. 2019;14(1):75.","journal-title":"Orphanet J Rare Dis"},{"key":"1610_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"issue":"4","key":"1610_CR13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40258-020-00624-2","volume":"19","author":"E Landfeldt","year":"2021","unstructured":"Landfeldt E, Pechmann A, McMillan HJ, Lochm\u00fcller H, Sejersen T. Costs of illness of spinal muscular atrophy: a systematic review. Appl Health Econ Health Policy. 2021;19(4):501\u201320.","journal-title":"Appl Health Econ Health Policy"},{"issue":"7","key":"1610_CR14","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","volume":"38","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Pogoryelova O, Sejersen T, Zethraeus N, Breiner A, Lochm\u00fcller H. Economic costs of myasthenia gravis: a systematic review. Pharmacoeconomics. 2020;38(7):715\u201328.","journal-title":"Pharmacoeconomics"},{"key":"1610_CR15","unstructured":"Wells GSB, O\u2019Connell J, Robertson J, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed 10 Sept 2025."},{"issue":"6","key":"1610_CR16","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1097\/PHM.0000000000000228","volume":"94","author":"JR Bach","year":"2015","unstructured":"Bach JR, Tran J, Durante S. Cost and physician effort analysis of invasive vs. noninvasive respiratory management of Duchenne muscular dystrophy. Am J Phys Med Rehabil. 2015;94(6):474\u201382.","journal-title":"Am J Phys Med Rehabil"},{"issue":"3","key":"1610_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1080\/21548331.2015.1033375","volume":"43","author":"CF Bell","year":"2015","unstructured":"Bell CF, Kurosky SK, Candrilli SD. Muscular dystrophy-related hospitalizations among male pediatric patients in the United States. Hosp Pract (1995). 2015;43(3):180\u20135.","journal-title":"Hosp Pract (1995)"},{"issue":"Suppl 1","key":"1610_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s10198-016-0782-5","volume":"17","author":"M Cavazza","year":"2016","unstructured":"Cavazza M, Kodra Y, Armeni P, De Santis M, L\u00f3pez-Bastida J, Linertov\u00e1 R, et al. Social\/economic costs and health-related quality of life in patients with Duchenne muscular dystrophy in Europe. Eur J Health Econ. 2016;17(Suppl 1):19\u201329.","journal-title":"Eur J Health Econ"},{"issue":"5","key":"1610_CR19","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/mus.27505","volume":"65","author":"KM Conway","year":"2022","unstructured":"Conway KM, Grosse SD, Ouyang L, Street N, Romitti PA. Direct costs of adhering to selected Duchenne muscular dystrophy care considerations: estimates from a Midwestern state. Muscle Nerve. 2022;65(5):574\u201380.","journal-title":"Muscle Nerve"},{"issue":"1","key":"1610_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1186\/s13023-025-03906-x","volume":"20","author":"J Diesing","year":"2025","unstructured":"Diesing J, Kirschner J, Pechmann A, K\u00f6nig J, Kunk L, Garcia TB, et al. Epidemiology, disease burden and costs of Duchenne muscular dystrophy in Germany: an observational, retrospective health claims data analysis. Orphanet J Rare Dis. 2025;20(1):429.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1610_CR21","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1007\/s12325-022-02117-1","volume":"39","author":"J Iff","year":"2022","unstructured":"Iff J, Zhong Y, Gupta D, Paul X, Tuttle E, Henricson E, et al. Disease progression stages and burden in patients with Duchenne muscular dystrophy using administrative claims supplemented by electronic medical records. Adv Ther. 2022;39(6):2906\u201319.","journal-title":"Adv Ther"},{"issue":"1","key":"1610_CR22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1186\/s13023-025-03794-1","volume":"20","author":"B Innis","year":"2025","unstructured":"Innis B, Jarvis J, Renteria T, Audhya I. Household costs in the United States for accommodating functional impairments associated with Duchenne muscular dystrophy: results from a caregiver survey. Orphanet J Rare Dis. 2025;20(1):301.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"1610_CR23","first-page":"1426","volume":"27","author":"AC Klimchak","year":"2021","unstructured":"Klimchak AC, Szabo SM, Qian C, Popoff E, Iannaccone S, Gooch KL. Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage. J Manag Care Spec Pharm. 2021;27(10):1426\u201337.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"1610_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s41669-021-00303-5","volume":"6","author":"P Labisa","year":"2022","unstructured":"Labisa P, Andreozzi V, Mota M, Monteiro S, Alves R, Almeida J, et al. Cost of illness in patients with Duchenne muscular dystrophy in Portugal: the COIDUCH study. Pharmacoecon Open. 2022;6(2):211\u20138.","journal-title":"Pharmacoecon Open."},{"issue":"2","key":"1610_CR25","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40273-016-0461-5","volume":"35","author":"E Landfeldt","year":"2017","unstructured":"Landfeldt E, Alfredsson L, Straub V, Lochmuller H, Bushby K, Lindgren P. Economic evaluation in Duchenne muscular dystrophy: model frameworks for cost-effectiveness analysis. Pharmacoeconomics. 2017;35(2):249\u201358.","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"1610_CR26","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1212\/WNL.0000000000000669","volume":"83","author":"E Landfeldt","year":"2014","unstructured":"Landfeldt E, Lindgren P, Bell CF, Schmitt C, Guglieri M, Straub V, et al. The burden of Duchenne muscular dystrophy: an international, cross-sectional study. Neurology. 2014;83(6):529\u201336.","journal-title":"Neurology"},{"issue":"3","key":"1610_CR27","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/mus.23942","volume":"49","author":"J Larkindale","year":"2014","unstructured":"Larkindale J, Yang W, Hogan PF, Simon CJ, Zhang Y, Jain A, et al. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve. 2014;49(3):431\u20138.","journal-title":"Muscle Nerve"},{"issue":"2","key":"1610_CR28","first-page":"205","volume":"31","author":"N Posner","year":"2025","unstructured":"Posner N, Manjelievskaia J, Talaga AK, Richards M, Lew CR, Merla V, et al. Real-world treatment and health care utilization among patients with Duchenne muscular dystrophy by race and ethnicity in a Medicaid population. J Manag Care Spec Pharm. 2025;31(2):205\u201313.","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"1610_CR29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3233\/JND-230133","volume":"11","author":"JH Rudolfsen","year":"2024","unstructured":"Rudolfsen JH, Vissing J, Werlauff U, Olesen C, Illum N, Olsen J, et al. Burden of disease of Duchenne muscular dystrophy in Denmark - A national register-based study of individuals with Duchenne muscular dystrophy and their closest relatives. J Neuromuscul Dis. 2024;11(2):443\u201357.","journal-title":"J Neuromuscul Dis."},{"issue":"1","key":"1610_CR30","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13023-023-02767-6","volume":"18","author":"NB Schneider","year":"2023","unstructured":"Schneider NB, Roos EC, Staub ALP, Bevilacqua IP, de Almeida AC, de Camargo Martins T, et al. Estimated costs for Duchenne muscular dystrophy care in Brazil. Orphanet J Rare Dis. 2023;18(1):159.","journal-title":"Orphanet J Rare Dis"},{"key":"1610_CR31","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13023-014-0210-9","volume":"9","author":"O Schreiber-Katz","year":"2014","unstructured":"Schreiber-Katz O, Klug C, Thiele S, Schorling E, Zowe J, Reilich P, et al. Comparative cost of illness analysis and assessment of health care burden of Duchenne and Becker muscular dystrophies in Germany. Orphanet J Rare Dis. 2014;9:210.","journal-title":"Orphanet J Rare Dis"},{"key":"1610_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.vhri.2022.08.006","volume":"33","author":"ZH Shehata","year":"2023","unstructured":"Shehata ZH, Rabea H, El Sherif R, Abdelrahim ME, Dawoud DM. Estimating societal cost of illness and patients\u2019 quality of life of Duchenne muscular dystrophy in Egypt. Value Health Reg Issues. 2023;33:10\u20136.","journal-title":"Value Health Reg Issues"},{"issue":"6","key":"1610_CR33","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/mus.24965","volume":"53","author":"LJ Teoh","year":"2016","unstructured":"Teoh LJ, Geelhoed EA, Bayley K, Leonard H, Laing NG. Health care utilization and costs for children and adults with Duchenne muscular dystrophy. Muscle Nerve. 2016;53(6):877\u201384.","journal-title":"Muscle Nerve"},{"issue":"6","key":"1610_CR34","first-page":"633","volume":"23","author":"S Thayer","year":"2017","unstructured":"Thayer S, Bell C, McDonald CM. The direct cost of managing a rare disease: assessing medical and pharmacy costs associated with Duchenne muscular dystrophy in the United States. J Manag Care Spec Pharm. 2017;23(6):633\u201341.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"1610_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40258-018-0418-2","volume":"17","author":"E Landfeldt","year":"2019","unstructured":"Landfeldt E, Zethraeus N, Lindgren P. Standardized questionnaire for the measurement, valuation, and estimation of costs of informal care based on the opportunity cost and proxy good method. Appl Health Econ Health Policy. 2019;17(1):15\u201324.","journal-title":"Appl Health Econ Health Policy"},{"issue":"1","key":"1610_CR36","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s41669-023-00450-x","volume":"8","author":"J Broomfield","year":"2024","unstructured":"Broomfield J, Hill M, Chandler F, Crowther MJ, Godfrey J, Guglieri M, et al. Developing a natural history model for Duchenne muscular dystrophy. Pharmacoecon Open. 2024;8(1):79\u201389.","journal-title":"Pharmacoecon Open."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01610-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01610-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01610-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:42:29Z","timestamp":1782211349000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01610-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1610"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01610-7","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Italfarmaco S.p.A. provided funding for bibliographic search support but did not compensate the authors for conducting this systematic literature review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dr. Erik Landfeldt is an employee of IQVIA, a contract research organization. Dr. Luca Bello has served as an advisor\/consultant for Italfarmaco, PTC Therapeutics, Sarepta Therapeutics, Roche, Edgewise Therapeutics, Santhera Pharmaceuticals, Reveragen BioPharma, and Boehringer Ingleheim; and has participated in research sponsored by Santhera, Italfarmaco, and Pfizer, outside the scope of the present work. Ms. Val\u00e9rie Deroo and Ms. Silene Giusti are employees of Italfarmaco S.p.A. Dr. Alfred Peter Born has attended advisory boards for Roche, Novartis, Pfizer, Biogen, and Italfarmaco; received research grants from Roche and Novartis; and has been a principal investigator for clinical studies for Novartis, Roche, and Biogen, outside the scope of the present work. Dr. Anne-Berit Ekstr\u00f6m has received honoraria for lectures or consultancy from Biogen, Novartis, PTC Therapeutics, Sarepta Therapeutics, Pfizer, Roche, and Italfarmaco, outside the scope of the present work. Ms. \u00c5berg reports no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The data supporting the findings of this study are available in the referenced publications.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Dr. Erik Landfeldt and Ms. Maria \u00c5berg conceived and designed the systematic review, implemented the searches, performed the screening and full-text review, extracted the data, and conducted the assessment of risk of bias. Dr. Erik Landfeldt led the analysis and interpretation of data with input from the other co-authors. Dr. Erik Landfeldt drafted the manuscript. All authors reviewed and edited the manuscript for important intellectual content and approved the final version as submitted.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}